Related Experiment Video
Updated: Feb 1, 2026

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Structural characterization of Atractylodes macrocephala polysaccharide 1 and its gut microbiota-mediated alleviation
Qingling Meng1, Mingjiang Mao1, Chenhuan Shentu1
1School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China.
Abstract:
Atractylodes macrocephala is a traditional Chinese medicinal (TCM) herb widely used for treating gastrointestinal disorders, yet the structural features and mechanisms of its polysaccharides remain insufficiently understood. In this study, we isolated and characterized a neutral glucan (A. macrocephala polysaccharide 1, AMP1) from the rhizome of A. macrocephala, with an average molecular weight of 7.98 kDa and a monosaccharide composition of glucose (Glc) and arabinose (Ara) in a molar ratio of approximately 129: 1. Structural analyses revealed that AMP1 is a glucan with a backbone composed of →4)-α-Glcp-(1→ residues and three types of branching units, namely →4)-α-Glcp-(1→, →6)-α-Glcp-(1→, and →6)-β-Glcp-(1→. Notably, the →6)-β-Glcp-(1→ branches appear to carry an additional substitution at the C-4 position. Functional assays demonstrated that AMP1 suppressed the release of pro-inflammatory cytokines, including IL-1β, IL-6, TNF-α, MCP-1, and iNOS, in LPS-stimulated macrophages. In vivo, AMP1 markedly ameliorated DSS-induced colitis in mice, as evidenced by a lower disease activity index (DAI), restoration of epithelial barrier integrity, and modulation of gut microbiota composition. Metabolomic profiling further revealed enrichment of beneficial microbial metabolites, implicating coordinated regulation of host-microbe metabolic pathways. Collectively, these findings establish AMP1 as a structurally defined polysaccharide with multifaceted protective effects, highlighting its therapeutic potential against ulcerative colitis (UC).
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Biosynthesis of Polysaccharides
Cellulose and Pectic Polysaccharides
As a cell matures, its cell wall specializes according to its type. For example, the...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

